Jonathan Bernstein, MD, discusses remibrutinib, c-kit inhibitors, and the current limits of biomarker-guided decision-making in chronic spontaneous urticaria.
Jonathan A. Bernstein, MD
Advertisement
Jonathan A. Bernstein, MD: University of Cincinnati
Articles by Jonathan A. Bernstein, MD
Bernstein discussed treatment sequencing, biomarker use, and evolving chronic spontaneous urticaria management strategies during an interview at EAC 2026.
Bernstein discussed the evolving role of biomarkers in chronic spontaneous urticaria at EAC 2026.
New phase 2 data reveals povorcitinib effectively reduces itch and hives in chronic spontaneous urticaria, showing promise as a treatment option.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
SimpleScreen CRC Blood Test Meets Endpoints in Clinical Validation Study
2
Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B
3
Eplontersen Misses Primary Endpoint in Phase 3 ATTR-CM Trial
4
Biologic Therapy for Asthma and COPD: Real-World Perspectives From APPs
5